Novus Therapeutics, Inc. (NVUS) is a publicly traded company in the Unknown sector. Across all available filings, 10 corporate insiders have executed 37 transactions totaling $9.9M, demonstrating a bullish sentiment with $4.7M in net insider flow. The most recent transaction on Dec 22, 2020 involved a transaction of 11,278 shares valued at $0.
No significant insider buying has been recorded for NVUS in the recent period.
No significant insider selling has been recorded for NVUS in the recent period.
Based on recent SEC filings, insider sentiment for NVUS is bullish with an Insider Alignment Score of 74/100 and a net flow of $4.7M. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
Insider trading at Novus Therapeutics, Inc. (NVUS) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 10 insiders are actively trading NVUS stock, having executed 37 transactions in the past 90 days. The most active insider is Global Management Lp Logos (Executive), who has made 9 transactions totaling $2.7M.
Get notified when executives and directors at NVUS file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Dec 22, 2020 | N. Lampert Mark | Executive | Conversion | 11,278 | $N/A | $0 | |
| Dec 22, 2020 | N. Lampert Mark | Executive | Conversion | 15,166 | $N/A | $0 | |
| Dec 22, 2020 | N. Lampert Mark | Executive | Conversion | 654,215 | $N/A | $0 | |
| Dec 22, 2020 | N. Lampert Mark | Executive | Conversion | 509,410 | $N/A | $0 | |
| Dec 22, 2020 | N. Lampert Mark | Executive | Conversion | 97,615 | $N/A | $0 | |
| Dec 22, 2020 | N. Lampert Mark | Executive | Conversion | 1,944 | $N/A | $0 | |
| Dec 2, 2020 | Gp Ltd. Orbimed Israel | Executive | Sale | 103,200 | $21.60 | $2.2M | Large |
| Oct 30, 2020 | Management Lp Logos Global | Executive | Sale | 12,942 | $26.64 | $344.8K | |
| Oct 30, 2020 | Management Lp Logos Global | Executive | Purchase | 15,000 | $26.17 | $392.6K | |
| Oct 30, 2020 | Management Lp Logos Global | Executive | Sale | 27 | $27.02 | $730 | |
| Oct 30, 2020 | Management Lp Logos Global | Executive | Purchase | 12,942 | $25.88 | $334.9K | |
| Oct 30, 2020 | Management Lp Logos Global | Executive | Purchase | 9,098 | $25.55 | $232.5K | |
| Oct 30, 2020 | Management Lp Logos Global | Executive | Purchase | 15,000 | $26.48 | $397.2K | |
| Oct 30, 2020 | Management Lp Logos Global | Executive | Purchase | 4,000 | $25.97 | $103.9K | |
| Oct 30, 2020 | Management Lp Logos Global | Executive | Purchase | 31,000 | $24.53 | $760.4K | Large |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Purchase(P) | 15 | $7.3M | 73.5% |
Sale(S) | 10 | $2.6M | 26.5% |
Conversion(C) | 6 | $0 | 0.0% |
Award(A) | 6 | $0 | 0.0% |
Insiders at Novus Therapeutics, Inc. are accumulating shares at an accelerated pace. With 10 insiders making 37 transactions totaling $7.3M in purchases versus $2.6M in sales, the net buying activity of $4.7M signals strong executive confidence. Global Management Lp Logos (Executive) leads the buying activity with $2.7M in transactions across all time.